Financial Ratios

MYLAN LABORATORIES LTD.

NSE : NABSE : 524794ISIN CODE : INE604D01023Industry : Pharmaceuticals & DrugsHouse : MNC
BSE209.350 (0 %)
PREV CLOSE ( ) 209.35
OPEN PRICE ( ) 208.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 209.35 (2)
VOLUME 50392
TODAY'S LOW / HIGH ( )208.80 211.00
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
Select year
ParticularsMar2020Mar2019Mar2018Mar2017Mar2016
Operational & Financial Ratios
   Earnings Per Share (Rs)7.46-16.77-13.59-19.28-5.53
   CEPS(Rs)58.5747.5960.5749.7643.37
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)289.91294.65315.98333.15280.28
   Tax Rate(%)56.60-17.14-13.7326.3256.02
Margin Ratios
   Core EBITDA Margin(%)18.5215.8419.0114.8013.16
   EBIT Margin(%)10.364.375.462.284.31
   Pre Tax Margin(%)3.42-3.18-3.02-6.62-3.22
   PAT Margin (%)1.48-3.72-3.43-4.88-1.42
   Cash Profit Margin (%)11.6510.5715.3012.5911.11
Performance Ratios
   ROA(%)0.94-2.12-1.67-2.22-0.71
   ROE(%)2.55-5.49-4.19-6.29-2.37
   ROCE(%)8.072.993.131.252.78
   Asset Turnover(x)0.630.570.490.460.50
   Sales/Fixed Asset(x)0.760.700.640.680.89
   Working Capital/Sales(x)1.541.511.541.661.73
Efficiency Ratios
   Fixed Capital/Sales(x)1.321.421.561.481.13
   Receivable days130.53121.07136.54127.64101.10
   Inventory Days136.81142.28138.10137.24132.78
   Payable days133.58145.22147.62130.47132.89
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)0.000.000.000.000.00
   Price/Book(x)0.000.000.000.000.00
   Yield(%)
   EV/Net Sales(x)0.690.780.880.951.12
   EV/Core EBITDA(x)3.374.183.654.826.63
   EV/EBIT(x)6.6817.8316.1941.7025.89
   EV/CE(x)0.440.450.440.450.48
   M Cap / Sales0.000.000.000.000.00
Growth Ratio
   Net Sales Growth(%)11.5713.810.161.6420.49
   Core EBITDA Growth(%)22.80-12.2422.6818.747.59
   EBIT Growth(%)164.68-8.90139.52-46.44-35.53
   PAT Growth(%)144.49-23.3929.53-248.46-200.35
   EPS Growth(%)144.49-23.3929.53-248.46-178.00
Financial Stability Ratios
   Total Debt/Equity(x)1.221.201.111.141.60
   Current Ratio(x)3.463.323.023.042.43
   Quick Ratio(x)2.081.801.791.821.45
   Interest Cover(x)1.490.580.640.260.57
   Total Debt/Mcap(x)

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.